<DOC>
	<DOC>NCT02170935</DOC>
	<brief_summary>To determine the PK profile of a single dose 150 mg BIBR 1048, oral capsule, administered 1-3 hours post surgery in hip replacement patients.</brief_summary>
	<brief_title>Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Patients scheduled to undergo a primary elective total hip replacement Male or female being 18 years or older (women of child bearing potential may not be included) Patients weighing at least 40 kg Written informed consent for participation Bleeding disorders, e.g. history of intracranial, intraocular, gastrointestinal or pulmonary bleeding, known thrombocytopenia, history of haemorrhagic stroke Known renal disease Known liver disease, alcohol or drug misuse Known malignancy Treatment with another study drug in the past month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>